Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.61 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.56 |
| ▸ | EED | O75530 | 4/20 | 0.49 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14717967 | 1.00 | EZH2 (0.61) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14933199 | 1.00 | EZH2 (0.61) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL17229174 | 0.90 | EZH2 (0.61) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL12180172 | 0.85 | EZH2 (0.68) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL14717553 | 0.81 | EZH2 (0.71) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL2594806 | 0.81 | EZH2 (0.75) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL12180088 | 0.80 | EZH2 (0.72) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19620890 | 0.77 | EZH2 (0.70) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL12180111 | 0.77 | EZH2 (0.66) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL19620822 | 0.77 | EZH2 (0.66) | EZH2EZH1EEDSUZ12HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |